Jinping Yuan1, Hongqiang Chen2, Ru Yan1, Shaoshan Cui3, Yuan-Hong Li1, Yan Wu1, Xing-Hua Gao1, Hong-Duo Chen1. 1. Department of Dermatology, The First Hospital of China Medical University, Shenyang. 2. Department of general surgery, Shandong qianfoshan hospital, Jinan. 3. Department of Dermatology, The first affiliated hospital of Dalian medical university, Dalian, China.
Abstract
BACKGROUND: Stable non-segmental vitiligo is often resistant to conventional therapies. OBJECTIVES: The purpose of this study was to investigate the effect of three types of fractional lasers in the treatment of stable non-segmental vitiligo. MATERIALS & METHODS: Twenty patients were enrolled in the study. The vitiligo lesions of each patient were divided into four treatment parts, and all parts were treated with narrowband ultraviolet-B (NB-UVB). Three of the four parts were respectively treated with three types of fractional lasers (two ablative 10,600-nm CO2 lasers and one non-ablative 1,565-nm laser), followed by topical betamethasone solution application. The treatment period lasted six months. Efficacy and satisfaction were respectively assessed by dermatologists and patients. RESULTS: The ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, achieved marked to excellent improvement on white patches assessed by dermatologists. Patients showed high satisfaction scores for the treatments. The non-ablative 1,565-nm fractional laser did not provide any further benefit in the treatment of vitiligo. No severe adverse events developed for any of the treatments. CONCLUSION: The treatment protocol with ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, was suitable for stable non-segmental vitiligo. For vitiligo, the ablative fractional CO2 laser is more effective than the non-ablative fractional laser.
BACKGROUND: Stable non-segmental vitiligo is often resistant to conventional therapies. OBJECTIVES: The purpose of this study was to investigate the effect of three types of fractional lasers in the treatment of stable non-segmental vitiligo. MATERIALS & METHODS: Twenty patients were enrolled in the study. The vitiligo lesions of each patient were divided into four treatment parts, and all parts were treated with narrowband ultraviolet-B (NB-UVB). Three of the four parts were respectively treated with three types of fractional lasers (two ablative 10,600-nm CO2 lasers and one non-ablative 1,565-nm laser), followed by topical betamethasone solution application. The treatment period lasted six months. Efficacy and satisfaction were respectively assessed by dermatologists and patients. RESULTS: The ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, achieved marked to excellent improvement on white patches assessed by dermatologists. Patients showed high satisfaction scores for the treatments. The non-ablative 1,565-nm fractional laser did not provide any further benefit in the treatment of vitiligo. No severe adverse events developed for any of the treatments. CONCLUSION: The treatment protocol with ablative CO2 lasers, in combination with topical betamethasone solution and NB-UVB, was suitable for stable non-segmental vitiligo. For vitiligo, the ablative fractional CO2 laser is more effective than the non-ablative fractional laser.